Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
George G Zhanel, Tamiko Hisanaga, Aleksandra Wierzbowski & Daryl J Hoban. (2006) Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia. Therapeutics and Clinical Risk Management 2:1, pages 59-75.
Read now
Read now
Daryl J Hoban & George G Zhanel. (2006) Clinical implications of macrolide resistance in community-acquired respiratory tract infections. Expert Review of Anti-infective Therapy 4:6, pages 973-980.
Read now
Read now
D.J. Bast, L. Dresser, C.L. Duncan, S.E. Walker, L.A. Mandell, D.E. Low & J.C.S. De Azavedo. (2006) Short-Course Therapy of Gemifloxacin Effective Against Pneumococcal Pneumonia in Mice. Journal of Chemotherapy 18:6, pages 634-640.
Read now
Read now
. (2004) Comments on Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin and Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin or 10 days. Current Medical Research and Opinion 20:12, pages 1895-1897.
Read now
Read now
Michael S. Niederman, Joanne R. Chang, John Stewart, Carl V. Asche, Bruce Lavin, Roomi Nusrat & Sean D. Sullivan. (2004) Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials. Current Medical Research and Opinion 20:7, pages 969-980.
Read now
Read now
Michael S. Niederman, Joanne R. Chang, John Stewart, Roomi Nusrat & Richard B. Nieman. (2004) Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin. Current Medical Research and Opinion 20:5, pages 749-756.
Read now
Read now
Articles from other publishers (17)
Miranda So, Jonathan Hand, Graeme Forrest, Stephanie M. Pouch, Helen Te, Monica I. Ardura, Rachel M. Bartash, Darshana M. Dadhania, Jeffrey Edelman, Dilek Ince, Margaret R. Jorgenson, Sarah Kabbani, Erika D. Lease, Deborah Levine, Linda Ohler, Gopi Patel, Jennifer Pisano, Michael L. Spinner, Lilian Abbo, Elizabeth C. Verna & Shahid Husain. (2022) White paper on antimicrobial stewardship in solid organ transplant recipients. American Journal of Transplantation 22:1, pages 96-112.
Crossref
Crossref
A. I. Sinopalnikov. (2018) Short antibiotic courses in community-acquired pneumonia in adults: less is better. Medical Council:15, pages 124-130.
Crossref
Crossref
Jesús López-Alcalde, Ricardo Rodriguez-Barrientos, Jesús Redondo-Sánchez, Javier Muñoz-Gutiérrez, José María Molero García, Carmen Rodríguez-Fernández, Julio Heras-Mosteiro, Jaime Marin-Cañada, Jose Casanova-Colominas, Amaya Azcoaga-Lorenzo, Virginia Hernandez Santiago & Manuel Gómez-García. (2018) Short-course versus long-course therapy of the same antibiotic for community-acquired pneumonia in adolescent and adult outpatients. Cochrane Database of Systematic Reviews 2018:9.
Crossref
Crossref
C. Wintenberger, B. Guery, E. Bonnet, B. Castan, R. Cohen, S. Diamantis, P. Lesprit, L. Maulin, Y. Péan, E. Peju, L. Piroth, J.P. Stahl, C. Strady, E. Varon, F. Vuotto & R. Gauzit. (2017) Proposal for shorter antibiotic therapies. Médecine et Maladies Infectieuses 47:2, pages 92-141.
Crossref
Crossref
Talitha I. Verhoef & Stephen Morris. (2015) Cost-effectiveness and Pricing of Antibacterial Drugs. Chemical Biology & Drug Design 85:1, pages 4-13.
Crossref
Crossref
Marilia Rita Pinzone, Bruno Cacopardo, Lilian Abbo & Giuseppe Nunnari. (2014) Duration of Antimicrobial Therapy in Community Acquired Pneumonia: Less Is More. The Scientific World Journal 2014, pages 1-8.
Crossref
Crossref
David C. Rhew. 2009. Evidence‐Based Infectious Diseases. Evidence‐Based Infectious Diseases
73
82
.
Nikole M Scalera & Thomas M File. (2007) How long should we treat community-acquired pneumonia?. Current Opinion in Infectious Diseases 20:2, pages 177-181.
Crossref
Crossref
E. Denes. (2006) Quel antibiotique pour une pneumonie aiguë communautaire de l'adulte ?. Médecine et Maladies Infectieuses 36:11-12, pages 718-733.
Crossref
Crossref
Bernhard Schwarz & Sylvia Nanz. (2013) Eine Kostenanalyse von Telithromycin im Vergleich zu Clarithromycin und Amoxicillin/Clavulansäure in der Behandlung von Patienten mit ambulant erworbener Pneumonie oder akuter Exazerbation einer chronischen Bronchitis in ÖsterreichCost analysis of telithromycin versus clarithromycin and amoxicillin/clavulanic acid in the treatment of patients with community-acquired pneumonia or acute exacerbations of chronic bronchitis. PharmacoEconomics German Research Articles 4:1, pages 31-45.
Crossref
Crossref
Ronald F. Grossman, John C. Rotschafer & James S. Tan. (2005) Antimicrobial treatment of lower respiratory tract infections in the hospital setting. The American Journal of Medicine 118:7, pages 29-38.
Crossref
Crossref
John Segreti, Hans R. House & Robert E. Siegel. (2005) Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. The American Journal of Medicine 118:7, pages 21-28.
Crossref
Crossref
Thomas G. Slama, Alpesh Amin, Stephen A. Brunton, Thomas M. FileJrJr, Gary Milkovich, Keith A. Rodvold, Daniel F. Sahm, Joseph Varon & David WeilandJrJr. (2005) A clinician’s guide to the appropriate and accurate use of antibiotics: the Council for Appropriate and Rational Antibiotic Therapy (CARAT) criteria. The American Journal of Medicine 118:7, pages 1-6.
Crossref
Crossref
George G. Zhanel, Christel Johanson, Nancy Laing, Tamiko Hisanaga, Aleksandra Wierzbowski & Daryl J. Hoban. (2005)
Pharmacodynamic Activity of Telithromycin at Simulated Clinically Achievable Free-Drug Concentrations in Serum and Epithelial Lining Fluid against Efflux (
mefE
)-Producing Macrolide- Resistant
Streptococcus pneumoniae
for Which Telithromycin MICs Vary
. Antimicrobial Agents and Chemotherapy 49:5, pages 1943-1948.
Crossref
Crossref
Nishaminy Kasbekar & Pinak S. Acharya. (2005) Telithromycin: The first ketolide for the treatment of respiratory infections. American Journal of Health-System Pharmacy 62:9, pages 905-916.
Crossref
Crossref
Martin Kolditz, Michael Halank & Gert H??ffken. (2005) Short-Course Antimicrobial Therapy for Community-Acquired Pneumonia. Treatments in Respiratory Medicine 4:4, pages 231-239.
Crossref
Crossref
George G. Zhanel, Christel Johanson, Tamiko Hisanaga, Chris Mendoza, Nancy Laing, Ayman Noreddin, Aleksandra Wierzbowski & Daryl J. Hoban. (2004) Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations. Journal of Antimicrobial Chemotherapy 54:6, pages 1072-1077.
Crossref
Crossref